Compare Liquidia Corporation Common Stock (LQDA) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Liquidia Corporation Common Stock trades at $33.49 (market cap $2.40B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Liquidia Corporation Common Stock is the larger of the two by market cap, and Liquidia Corporation Common Stock is more actively traded (2,857,547 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LQDA | QURE | |
|---|---|---|
Market Cap | $2.40B | $1.48B |
Volume | 2,857,547 | 2,488,780 |
Sector | Health | Health |
52-Week High | $91.03 | $70.59 |
52-Week Low | $22.02 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.30B | $728.62M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
